Novartis CEO feels heat on U.S. generics, Cosentyx drop

ZURICH (Reuters) - Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news